Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from BioInvent International AB ( (SE:BINV) ).
BioInvent International AB and Transgene have announced the presentation of updated data from the Phase 1 part of their ongoing Phase 1/2a study of the oncolytic virus BT-001 at the ESMO 2025 Annual Meeting. The study, which involves using BT-001 in combination with pembrolizumab, has shown promising results, with clinical responses observed in some patients with advanced solid tumors. This development could enhance BioInvent’s position in the cancer immunotherapy market and provide new treatment options for patients with refractory tumors.
More about BioInvent International AB
BioInvent International AB is a biotechnology company specializing in the discovery and development of novel antibodies for cancer immunotherapy. The company focuses on creating first-in-class immune-modulatory therapies. Transgene, its collaborator, is a biotechnology company that designs and develops virus-based immunotherapies for cancer treatment, with a portfolio that includes viral immunotherapeutics and oncolytic viruses.
Average Trading Volume: 101,240
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.7B
For a thorough assessment of BINV stock, go to TipRanks’ Stock Analysis page.